Abstract

Taiwanese researchers have identified a new scaffold they say inhibits HCV NS3 helicase without the cytotoxicity associated with other inhibitors of the target. But drug developers think the compounds need to be significantly more specific and potent to be drug candidates.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.